Eli Lilly (NYSE: LLY) continued rollout through September 2026 of the early-access program for retatrutide (a once-weekly subcutaneous injectable GIP/GLP-1/glucagon triple agonist peptide for obesity) ahead of the Q1 2027 BLA submission plan confirmed after the July 23, 2026 TRIUMPH-2 and TRIUMPH-3 Phase 3 wins in obesity plus type 2 diabetes and obesity plus established cardiovascular disease. The 12 mg retatrutide dose produced 28.3% mean weight loss at 80 weeks in the TRIUMPH-1 Phase 3 obesity monotherapy trial reported in May 2026, the highest weight loss reported for any obesity therapy in a Phase 3 setting. TRIUMPH-4 (knee osteoarthritis, 68 weeks) added 28.7% weight loss plus improvements in pain and physical function. Seven Phase 3 readouts total are expected across the retatrutide program in 2026. Lilly management has framed retatrutide as the successor commercial franchise to Zepbound and Mounjaro, with launch anticipated 2027-2028 under the Most Favored Nation pricing framework that would apply from initial approval per the November 2025 pricing agreement.
Eli Lilly (NYSE: LLY) clarified that the retatrutide (once-weekly injectable GIP/GLP-1/glucagon triple agonist peptide) regulatory submission timeline was pushed from end-2026 to Q1 2027 as the company continues gathering manufacturing and quality control data required for the FDA Biologics License Application. TRIUMPH-1 (obesity without type 2 diabetes) Phase 3 readout updated documented 28.3% mean weight loss at 80 weeks on the 12 mg weekly injection arm in 2,339 participants, the largest weight-loss figure reported in any Phase 3 obesity trial to date. Combined with TRIUMPH-2 (obesity plus type 2 diabetes at up to 20.8% weight loss and 1.6 percentage point HbA1c reduction in 1,152 participants), TRIUMPH-3 (additional confirmatory data), and TRIUMPH-4 (obesity plus knee osteoarthritis at 28.7% weight loss and 75.8% WOMAC pain reduction), the retatrutide package now anchors four major indication frames. Additional TRIUMPH readouts expected across 2026 in obstructive sleep apnea, chronic lower back pain, and cardio-renal-metabolic outcomes will strengthen the label breadth. The Q1 2027 filing timeline shift is a modest delay from prior end-2026 signaling but reflects manufacturing-scale challenges typical of peptide APIs at the projected multi-billion-dollar commercial demand level (semaglutide and tirzepatide combined are already at roughly $80 billion annual revenue). Potential FDA approval expected in 2027 to 2028 following the standard 10-month review or 6-month priority review if a Priority Review Voucher (PRV) is deployed. Retatrutide will likely reshape the entire obesity drug class ceiling on the injectable side once approved.